Publications

 

A list of current publications is given below:

  • Orleans-Lindsay JK, Deru A, Craig JI, Prentice HG & Lowdell MW. In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukemic cells; a strategy for ex-vivo generation of CTL for immunotherapy. Clin Exp Immunol. 2003; 133(3): 467-7.
  • Todryk S, Birchall L, Erlich R, Halanek N, Orleans-Lindsay JK & Dalgleish AG. Cytokine gene transfection for autologous and allogeneic melanoma vaccine. Adv Exp Med Biol. 2001; 495: 365-8.
  • Orleans-Lindsay JK, Barber LD, Prentice HG & Lowdell MW. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function – implications for the adoptive immunotherapy of leukaemia. Clin Exp Immunol. 2001 Dec; 126(3): 403-11.
  • Todryk SM, Birchall LJ, Erlich R, Halanek N, Orleans-Lindsay JK & Dalgleish AG. Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines. Immunol. 2001; 102(2): 190-8.
  • Hrouda D, Todryk SM, Perry MJ, Souberbielle BE, *Kayaga J, Kirby RS & Dalgeish AG. Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer. Br J Urol. 2000; 86(6): 742-8.
  • *Kayaga J, Souberbielle BE, Sheikh N, Morrow WJ, Scott-Taylor T, Vile R, Chong H & Dalgleish AG. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Ther. 1999; 6(8): 1475-81.
  • Souberbielle BE, Westby M, Ganz S, *Kayaga J, Mendes R, Morrow WJ & Dalgleish AG. Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model. Gene Ther. 1998; 5(11): 1447-54.
  • Hrouda D, Souberbielle BE, *Kayaga J, Corbishley CM, Kirby RS & Dalgleish AG. Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer. Br J Urol. 1998; 82(6): 870-6.
* Maiden name